SG11201402876UA - Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof - Google Patents

Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof

Info

Publication number
SG11201402876UA
SG11201402876UA SG11201402876UA SG11201402876UA SG11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA
Authority
SG
Singapore
Prior art keywords
quinolylpyrrolopyrimidyl
fused
salt
ring compound
compound
Prior art date
Application number
SG11201402876UA
Other languages
English (en)
Inventor
Takeshi Sagara
Satoru Ito
Sachie Otsuki
Katsumasa Nonoshita
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201402876UA publication Critical patent/SG11201402876UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201402876UA 2012-02-23 2013-02-22 Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof SG11201402876UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012037565 2012-02-23
PCT/JP2013/054615 WO2013125709A1 (fr) 2012-02-23 2013-02-22 Composé à cycle fusionné de quinolyl-pyrrolo-pyrimidyl ou un sel associé

Publications (1)

Publication Number Publication Date
SG11201402876UA true SG11201402876UA (en) 2014-12-30

Family

ID=49005885

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402876UA SG11201402876UA (en) 2012-02-23 2013-02-22 Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof

Country Status (16)

Country Link
US (1) US8889666B2 (fr)
EP (1) EP2722332B1 (fr)
JP (1) JP5557963B2 (fr)
KR (1) KR101660145B1 (fr)
CN (1) CN104136438B (fr)
CA (1) CA2861980C (fr)
DK (1) DK2722332T3 (fr)
ES (1) ES2580530T3 (fr)
HK (1) HK1202862A1 (fr)
HU (1) HUE029343T2 (fr)
MX (1) MX351863B (fr)
PL (1) PL2722332T3 (fr)
RU (1) RU2581039C1 (fr)
SG (1) SG11201402876UA (fr)
TW (1) TWI496783B (fr)
WO (1) WO2013125709A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014129596A1 (fr) * 2013-02-22 2014-08-28 大鵬薬品工業株式会社 Procédé de production de composé tricyclique, et composé tricyclique apte à être produit par ledit procédé de production
WO2015025936A1 (fr) * 2013-08-22 2015-02-26 大鵬薬品工業株式会社 Nouveau composé substitué par une quinoline
CN111393446B (zh) * 2015-03-31 2022-12-20 大鹏药品工业株式会社 3,5-二取代的苯炔基化合物晶体
WO2017064558A1 (fr) * 2015-10-14 2017-04-20 大鵬薬品工業株式会社 Nouveau immunostimulant
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
CN108101905A (zh) 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
JP7065103B2 (ja) 2017-09-01 2022-05-11 大鵬薬品工業株式会社 エクソン18及び/又はエクソン21変異型egfr選択的阻害剤
CN115181104A (zh) * 2019-09-29 2022-10-14 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2022121967A1 (fr) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Inhibiteur de la tyrosine kinase de l'egfr et ses utilisations
CN115785107A (zh) * 2022-12-15 2023-03-14 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533172A (ja) 2005-03-17 2008-08-21 ノバルティス アクチエンゲゼルシャフト チロシン/スレオニンキナーゼ阻害剤、特にB−RAFキナーゼ阻害剤としての、N−[3−(1−アミノ−5,6,7,8−テトラヒドロ−2,4,4b−トリアザフルオレン−9−イル)−フェニル]ベンズアミド
EP1979002A2 (fr) * 2005-12-19 2008-10-15 OSI Pharmaceuticals, Inc. Combinaison d'un inhibiteur de l'igfr et d'un agent anticancéreux
MX2008012929A (es) * 2006-04-04 2008-12-17 Univ California Antagonistas de cinasa.
WO2008018881A1 (fr) 2006-08-10 2008-02-14 Osi Pharmaceuticals, Inc. Soufre porteur d'une substitution à noyau 6,6-bicyclique contenant des inhibiteurs hétérobicycliques de la protéine kinase
EP2081435B1 (fr) * 2006-09-22 2016-05-04 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
JP5347202B2 (ja) * 2007-03-28 2013-11-20 ファーマサイクリックス,インク. ブルトンチロシンキナーゼインヒビター
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
CA2803056C (fr) * 2010-06-23 2017-05-16 Hanmi Science Co., Ltd. Derives de pyrimidine fusionnes destines a l'inhibition de l'activite tyrosine kynase
NZ609957A (en) * 2010-11-01 2015-08-28 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
MX2014009991A (es) 2014-09-08
AU2013223052A1 (en) 2014-07-03
ES2580530T3 (es) 2016-08-24
PL2722332T3 (pl) 2016-10-31
CA2861980A1 (fr) 2013-08-29
CN104136438A (zh) 2014-11-05
HK1202862A1 (zh) 2015-10-09
TWI496783B (zh) 2015-08-21
EP2722332A1 (fr) 2014-04-23
DK2722332T3 (en) 2016-06-20
KR101660145B1 (ko) 2016-09-26
CN104136438B (zh) 2016-04-06
WO2013125709A1 (fr) 2013-08-29
EP2722332B1 (fr) 2016-04-20
HUE029343T2 (en) 2017-02-28
JPWO2013125709A1 (ja) 2015-07-30
CA2861980C (fr) 2016-11-08
TW201339160A (zh) 2013-10-01
MX351863B (es) 2017-10-30
RU2581039C1 (ru) 2016-04-10
JP5557963B2 (ja) 2014-07-23
KR20140117647A (ko) 2014-10-07
EP2722332A4 (fr) 2014-04-23
US8889666B2 (en) 2014-11-18
US20140057899A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
IL273276A (en) salt crystals
EP2842955A4 (fr) COMPOSÉ INHIBITEUR DE Trk
HK1188451A1 (zh) 咪唑並噁嗪化合物或其鹽
AP2014007810A0 (en) Imidazopyrrolidinone compounds
EP2925129A4 (fr) Composés pro-neurogènes
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2887803A4 (fr) Composés pro-neurogéniques
HK1202862A1 (zh) 喹啉基吡咯並嘧啶基稠環化合物或其鹽
HK1199730A1 (zh) 哌啶化合物或其鹽
EP2828262A4 (fr) Composés d'imidazotriazinone
GB201204985D0 (en) Compounds
GB201220843D0 (en) Compound
GB201204125D0 (en) Compounds
SI2836495T1 (sl) Spojine tetrahidropirolotiazina
HK1185079A1 (zh) 新型二環式化合物或其鹽
GB201209096D0 (en) Compounds
HK1215571A1 (zh) 二鹽酸科比思特
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
GB201217310D0 (en) Compounds
GB201216448D0 (en) Compound
AU2013223052B2 (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof
GB201222716D0 (en) Compound